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Four large randomised trials of paclitaxel in combination with platinum against a platinum-based control treatment have now
been published in full, representing around 88% (3588 out of 4057) of patients randomised into the eight known trials of this
question. There is substantial heterogeneity in the results of these four trials. Four main explanations for this heterogeneity
have been proposed: differences in the extent and timing of ‘crossover’ to taxanes in the control groups; differences in the
types of patient included; differences in the effectiveness of the research regimens used; differences in the effectiveness of the
control regimens used. In this study we examine whether any of these explanations is consistent with the pattern of results
seen in these trials. Each explanation suggests that a particular characteristic of each trial was responsible for the results
observed. For each explanation the trials were split into groups according to that characteristic, in order to partition the total
heterogeneity into that seen ‘within’ and ‘between’ groups of trials. If a particular explanation was consistent with the pattern
of results, we would expect to see relatively little heterogeneity within each group of trial results viewed in this way, with
most of the heterogeneity being between groups which are dissimilar with respect to the key characteristic. Heterogeneity
‘within’ and ‘between’ groups was formally compared using the F-ratio. If any explanation appeared to be consistent with the
results of the trials, it was considered whether the explanation was also consistent with other evidence available about these
regimens. Only one explanation appeared to be consistent with the pattern of results seen in these trials, and that was
differences in effectiveness of the control arms used in these trials. This suggests that the very positive results in favour of
paclitaxel/cisplatin seen in two of the trials may have been due to the use of a suboptimal control arm. There is no direct
evidence about the relative effectiveness of the control arms used in these trials, but indirect evidence is consistent with the
conclusion that the cyclophosphamide/cisplatin regimen used in two of the trials may be less effective than the control
regimens used in the other trials. Speciﬁc concerns about the choice of a cyclophosphamide/cisplatin control arm in the ﬁrst of
these trials to report were raised before the results of the other trials were known, i.e. before any heterogeneity had been
observed. Further investigation of this question would be useful. In the meantime, given all of the randomised evidence on the
efﬁcacy and toxicity associated with the regimens used in these trials, we conclude that single agent carboplatin is a safe and
effective ﬁrst-line treatment for women with advanced ovarian cancer.
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BACKGROUND
In many countries the combination of carboplatin plus paclitaxel has
become a standard ﬁrst-line therapy for women requiring
chemotherapy for ovarian cancer. Recently, however, evidence has
emerged questioning this approach. A systematic review by the
NHS Centre for Reviews and Dissemination in York, commissioned
by the NHS R&D Health Technology Assessment Programme (HTA)
on behalf of the National Institute for Clinical Excellence (NICE),
reviewed four trials that compared standard platinum-based treat-
ment against the combination of platinum and paclitaxel (Lister-
Sharp et al, 2000; Taxanes, 2002). At the time of this review three
of the four trials remained unpublished. These trials have now all
been published in full. In this study we examine the most recent
published results of the trials identiﬁed by this review. Full details
of the search strategy, methods and results of the original review
are contained in the assessment report produced for NICE, which
is published in monograph form by the HTA Programme (Lister-
Sharp et al, 2002; Taxanes, 2002; National Institute of Clinical Excel-
lence, URL http://www.nice.org.uk/).
Although there are a number of differences between these trials,
they all posed the same general question (Table 1). The ﬁrst of
these trials was GOG-111 (McGuire et al, 1993, 1995, 1996),
conducted by the Gynecology Oncology Group (GOG) in the
United States. This was ﬁrst presented at the annual meeting of
the American Society of Clinical Oncology (ASCO) in 1993 and
published in full in 1996. In GOG-111 410 patients were rando-
mised and the trial reported very positive results in favour of
paclitaxel/cisplatin compared with cyclophosphamide/cisplatin with
hazard ratio of 0.61 (95%CI 0.47–0.79) for overall survival. These
results were later conﬁrmed by a European-Canadian Intergroup
trial (OV10) (Piccart et al, 1997, 2000; Stuart et al, 1998; Trope
and Vergote, 1999), which randomised 680 patients between the Received 24 July 2002; revised 1 August 2002; accepted 5 August 2002
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www.bjcancer.comTable 1 Trials comparing paclitaxel/platinum combinations with a platinum-based control treatment
Trial Treatment regimens Patient group Accrual and dates Results available
Trials included in meta-analysis
GOG-111 Paclitaxel (135 mg m
72, 24 h) FIGO stage III (suboptimal) or IV 410 Abstract (McGuire et al, 1993) 379a
Cisplatin 75 mg m
72 April 1990 to March 1992 Abstract (McGuire et al, 1995)
Full paper (McGuire et al, 1996)
Cyclophosphamide 750 mg m
72
Cisplatin 75 mg m
72
Both 3 weekly for 6 cycles
GOG-132 Paclitaxel (135 mg m
72, 24 h) FIGO stage III (suboptimal) 424 Abstract (Muggia et al, 1997)
Cisplatin 75 mg m
72 or IV (3 arm trial, 648 in total) Full paper (Muggia et al, 2000)
March 1992 to May 1994
Cisplatin 100 mg m
72
Both 3 weekly for 6 cycles
(also included a third arm of single
agent paclitaxel (200 mg m
72,2 4h )
European-Canadian Paclitaxel (175 mg/m
72, 3 h) FIGO stage IIb–c, III and IV with 680 Abstract (Piccart et al, 1997)
Intergroup (OV10) Cisplatin 75 mg m
72 optimal or suboptimal residual April 1994 to August 1995 Abstract (Stuart et al, 1998)
disease Abstract (Trope et al, 1999)
Cyclophosphamide 750 mg m
72 Full paper (Piccart et al, 2000)
Cisplatin 75 mg m
72
Both 3 weekly for 6 cycles
ICON3 Paclitaxel (175 mg m
72, 3 h) FIGO stage I–IV, (any residual 2074 Abstract (Harper et al, 1999)
Carboplatin 6 AUC disease) (1421 choosing carboplatin Abstract (Colombo et al, 2000)
and 653 choosing CAP as Full paper (ICON Collaborators, 2002)
Carboplatin 6 AUC or control regimen)
Cyclophosphamide 750 mg m
72 February 1995 to October 1998
Doxorubicin 75 mg m
72
Cisplatin 75 mg m
72
All 3 weekly for 6 cycles
Trials not included in meta-analysis
GOG-114 Paclitaxel (175 mg m
72, 24 h) FIGO stage III with optimal *140 (3 arm trial, 589 in Not yet reported; results of other
Cisplatin 75 mg m
72 residual disease total; CP arm closed early) two arms:
August 1992 to April 1995 Abstract (Markman et al, 1998)
Cyclophosphamide 750 mg m
72 Full paper (Marklman et al, 2001)
Cisplatin 75 mg m
72
Both 3 weekly for 6 cycles
Wolf Paclitaxel (175 mg m
72, no FIGO stage IIb, III and IV 212 Abstract (Wolf et al, 1999)
infusion time stated)
Carboplatin 6 AUC
Carboplatin 6 AUC
Cyclophosphamide 600 mg m
72
Both 4 weekly for 6 cycles
Gennatas Paclitaxel (175 mg m
72, no FIGO stage IIIa–c and IV 85 Abstract (Gennatas et al, 2000)
infusion time stated)
Cisplatin 75 mg m
72
Cyclophosphamide 700 mg m
72
Cisplatin 75 mg m
72
6 cycles, no length of cycles
Simsek Paclitaxel (135 mg m
72, no FIGO stage III–IV, optimal 32 Full paper (Simsek et al, 1999) (Turkish)
infusion time stated) debulking surgery performed
Cisplatin 75 mg m
72
Cyclophosphamide 750 mg m
72
Cisplatin 75 mg m
72
No number of cycles or length
of cycles
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1997 and was published in May 2000. However, these results were
contradicted by a further GOG trial, GOG-132 (Muggia et al, 1997,
2000), comparing single agent cisplatin against the same paclitaxel/
cisplatin combination used in GOG-111, with 424 patients rando-
mised between these two arms (648 randomised in total between
three arms, with the third arm being single agent paclitaxel). The
results of GOG-132, also presented at ASCO in 1997 and published
in January 2000, were very different, suggesting no beneﬁt to the
paclitaxel/cisplatin regimen.
These data have generated considerable controversy. Although
several possible explanations were suggested at the time, it was
difﬁcult to draw ﬁrm conclusions as to the appropriate interpreta-
tion of the conﬂicting results (Muggia et al, 1997, 2000; Sandercock
et al, 1998). However, we now have the results of a fourth trial,
ICON3 (Harper, 1999; Colombo, 2000; ICON Collaborators,
2002), which might help to clarify some of these issues. ICON3
compared paclitaxel/carboplatin against a control arm of single-
agent carboplatin or the three drug CAP combination (cyclopho-
sphamide, doxorubicin and cisplatin). ICON3 closed to accrual
of new patients in 1998 with 2074 patients randomised. The preli-
minary results were presented at ASCO in May 1999 and are now
published in full by the International Collaborative Ovarian
Neoplasm Collaborators (ICON Collaborators, 2002).
THE EXPLANATIONS FOR THE RESULTS OF GOG-132
The results of GOG-132 were somewhat unexpected, given the
earlier results of GOG-111 and the preliminary data from OV10.
The GOG-132 investigators put forward a number of possible
explanations for their unexpected results including the play of
chance, the different control regimens used in the trials, and the
fact that a high proportion of patients on the single agent cisplatin
(control) arm in GOG-132 went on to receive some treatment with
paclitaxel prior to clinical evidence of disease progression. In rela-
tion to this last point, it was reported that around half of the
patients on each of the three arms of the trial had gone on to
receive some form of additional treatment after protocol
chemotherapy but before progression of disease, with a proportion
of those on the single agent cisplatin control arm receiving paclitax-
el at this time. This early crossover has been widely assumed to
account for the failure to detect any beneﬁt for paclitaxel/cisplatin
in the trial (Gore et al, 1997; Adams et al, 1998; National Cancer
Guidance Steering Group, 1999). However, a number of indivi-
duals, including the GOG-132 investigators (Muggia et al, 2000;
Torri et al, 2000), have been reluctant to accept that this explana-
tion is necessarily sufﬁcient to explain the difference in the results.
The most obvious difﬁculty is that only a minority (24%) of the
single agent cisplatin control group crossed over to paclitaxel before
progression. Whilst this is certainly a substantial minority, if the
true difference between single agent cisplatin as used in GOG-132
and paclitaxel/cisplatin were as large as the difference observed in
GOG-111 and OV10 (both using a control arm of cyclophospha-
mide/cisplatin) it seems unlikely that crossover to paclitaxel in
just one quarter of the control patients could apparently eliminate
the difference between the two regimens, i.e. to give a relative risk
of death (hazard ratio) of around one for both progression-free
survival and overall survival (see Figure 1).
The credibility of the notion that crossover could be solely
responsible for the unexpected results of GOG-132 is further ques-
tioned if comparisons between response rates are examined.
Although not as reliable or perhaps clinically relevant as the
endpoints of progression-free and overall survival, this is the only
outcome measure which could not have been affected by early
crossover in any of the trials. Both GOG-111 and OV10 report
large and statistically signiﬁcant differences in clinical response
rates in favour of paclitaxel/cisplatin; overall (complete plus
partial) response rate 60% vs 73% (P=0.01) in GOG-111 and
45% vs 59% (P=0.01) in OV10. In contrast, GOG-132 reports
identical response rates for single agent cisplatin as for cisplatin/
paclitaxel, 67% vs 67% respectively, with complete responses in
42% vs 43%, respectively. Thus the inconsistency in the results
Progression free survival
(no. events/no. entered)
Paclitaxel/platinum Platinum based O-E Variance
GOG111
GOG132
OV10
ICON3
139/184
179/201
261/342
516/710
   174/202
   175/200
   281/338
1022/1364
–31.74
5.24
–41.43
–26.15
76.38
90.01
137.58
348.87
c
2 het = 14.38 (3 d.f.)   P = 0.002
GOG111
GOG132
OV10
ICON3
Overall survival
(no. events/no. entered)
Paclitaxel/platinum Platinum based O-E Variance
98/184
154/201
183/342
435/710
137/202
158/200
220/338
830/1364
–28.17
–0.83
–31.11
–5.55
56.98
83.05
98.84
285.61
c
2 het = 15.62 (3 d.f.)   P = 0.001
0                   0.5                    1                     1.5                   2
Paclitaxel/platinum better Platinum-based better
Hazard ratio
0                   0.5                    1                    1.5                   2
Paclitaxel/platinum better Platinum-based better
Hazard ratio
Figure 1 Results of trials comparing paclitaxel/platinum vs a platinum-based control arm.
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endpoints measured both before and after any crossover occurred,
giving further reason to doubt the adequacy of ‘early crossover’ as
an explanation for the different results.
RESOLVING SOME UNANSWERED QUESTIONS
The results of these four trials (GOG-111, GOG-132, OV10 and
ICON3) have now all been published in full (Stuart et al, 1998;
Muggia et al, 2000; Piccart et al, 2000; ICON Collaborators,
2002) and it therefore seems appropriate to reassess all the
evidence. The total number of patients in these four trials is
3588. We have identiﬁed four further trials in Table 1 (Simsek et
al, 1999; Wolf et al, 1999; Gennatas et al, 2000; Markman et al,
2001). The results of these trials are not available in any usable
form for the following reasons. The GOG-114 trial (Markman et
al, 2001) (with approximately 140 patients) as far as we are aware
has never reported any results for the (non-taxane-containing)
control arm, the trials of Wolf et al (1999) (212 patients) and
Gennatas et al (2000) (89 patients) have been reported in abstract
form only, while the small trial of Simsek et al (1999) (32 patients)
has been reported in Turkish only and it has not been possible to
extract relevant information. Thus this review is based on the four
largest trials from which we can extract relevant data. These trials
represent 88% (3588 out of 4057) of all the patients randomised
into known trials of this question.
A naive meta-analysis, which simply pools results without
paying attention to differences in the results of four trials, would
suggest a beneﬁt to paclitaxel/platinum, smaller than that originally
expected on the basis of GOG-111, but still statistically (and
perhaps clinically) signiﬁcant. Using the ‘ﬁxed effects’ model, the
pooled result for progression-free survival gives an estimated
hazard ratio of 0.87 with a 95% conﬁdence interval of (0.80,
0.94), P=0.0003. The pooled result for overall survival is similar,
with a pooled hazard ratio of 0.88, 95% conﬁdence interval of
(0.81, 0.96), P=0.004.
However, there is clear statistical heterogeneity in these results;
for progression-free survival w
2
(het)=14.37 (3 d.f.), P=0.002 and
for overall survival w
2
(het)=15.62 (3 d.f.), P=0.001. There is there-
fore strong evidence that these trials are not providing answers
to the same question. Simply pooling the results under these
circumstances is inappropriate. An alternative sometimes used in
these circumstances is a ‘random effects’ model. Using this
approach, the pooled results for progression-free and overall survi-
val give estimated hazard ratios of 0.84 with a 95% conﬁdence
interval of (0.70, 1.01; P=0.06) and 0.82 (0.66, 1.02; P=0.08)
respectively. However, the ‘random effects’ analysis is far from
satisfactory, because it is very sensitive to the assumptions under-
lying the ‘random’ element. A modest change in these
assumptions (which are untestable) leads to very different results.
Thus both of these analyses are not satisfactory. Further they leave
the most important question unanswered: why is there such a clear
conﬂict (heterogeneity) in the results of these four trials?
Four possible explanations for this heterogeneity are proposed:
(1) differences in extent of crossover (including crossover prior
to progression); (2) differences in the type of patients included
in each trial; (3) differences in the research arms and (4) differ-
ences in the control arms.
We considered each of these hypotheses in turn. For each one,
the approach used was to consider whether each explanation is
plausible (could it give rise to heterogeneity) and, if so, whether
it is consistent with the observed data (i.e. does it explain the
heterogeneity observed), and if so, whether it is also consistent
with evidence external to these trials.
We used a ‘meta-regression’ approach (Thompson and Sharp,
1999) to examine consistency between each explanation and the
observed data. Each explanation suggests that a particular charac-
teristic of each trial was responsible for the results observed. For
each explanation we therefore split the trials into groups accord-
ing to that characteristic, allowing us to partition the total
heterogeneity into that seen ‘within’ and ‘between’ groups of
trials. If a particular explanation was consistent with the pattern
of results, we would expect to see relatively little heterogeneity
within each group of trial results viewed in this way, with most
of the heterogeneity being between groups which are dissimilar
with respect to the key characteristic. Heterogeneity ‘within’ and
‘between’ groups was formally compared using the F-ratio. If a
substantial proportion of the total observed heterogeneity is
successfully ‘explained’ by the analysis, then the F-ratio comparing
‘between group’ to ‘within group’ heterogeneity should be large;
the observed value may be compared to the corresponding F
distribution to establish whether it is larger than could reasonably
be expected by chance. Note that this is a one-sided test of the
hypothesis that heterogeneity between groups is greater than that
within groups; the hypothesis, that within group heterogeneity is
greater, is of no interest here, and has no meaningful interpreta-
tion.
If any explanation appeared to be consistent with the results of
the trials, we went on to consider whether the explanation was also
consistent with other evidence available about these regimens.
EXTENT OF CROSSOVER
The majority of patients whose disease progresses after ‘ﬁrst-line’
chemotherapy will go on to receive further courses of chemother-
apy (‘second-line’ treatment). This ‘second-line’ regimen used may
be similar or different from that used ﬁrst-line, depending on the
observed duration of response to the agent(s) used ﬁrst-line, the
suitability of alternative agents and the preferences of both clinician
and patient. Also patients who have a poor response to the original
ﬁrst-line treatment may switch to an alternative treatment in the
absence of disease progression. Occasionally patients may receive
‘consolidation’ treatment after ﬁrst-line treatment is completed
but before clinical progression is noted and this may include addi-
tional cycles of the ﬁrst-line regimen, an alternative chemotherapy
regimen, or non-chemotherapy treatment (such as radiotherapy or
hormonal treatment).
GOG-132 is the only trial to report substantial crossover to
taxanes in the control arm prior to progressive disease being
reported; OV10 reported 4% and ICON3 3% of control patients
receiving taxane-based treatment at this time. No published infor-
mation on additional treatments given prior to progression is
available for GOG-111. However, in personal communication with
the GOG it has been reported that very few patients in GOG-111
would have received any taxane therapy before progression on the
control arm because of the limited availability of taxanes at that
time. All trials apart from GOG-111 report substantial crossover
in the platinum-based control arm to second-line taxane-based
treatment after progressive disease was noted; GOG-111 reports
that there was little crossover to taxanes in the control group.
Comparing groups with different amounts of crossover before
progression (Figure 2 and Table 2) there is no indication that
the heterogeneity between groups is substantially greater than that
within groups for progression-free (F1,2=0.85, P=0.45) or overall
survival (F1,2=0.18, P=0.71).
Within the group of trials reporting substantial crossover on
progression heterogeneity between groups is not substantially
greater than that within the groups (F1,2=2.53, P=0.25) for overall
survival (Table 2). The results are similar for progression-free
survival, although clearly the amount of crossover on progression
could not reasonably be expected to inﬂuence these results.
This suggests that the heterogeneity in the results of these trials
cannot be accounted for by crossover either before or after
progression.
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Little or no crossover before progression
GOG111
OV10
ICON3
GOG132
Substantial crossover before progression
Extent of crossover on progression
Little or no crossover on progression
GOG111
Substantial crossover on progression
GOG132
OV10
ICON3
Volume of residual disease following surgery
Optimal residual disease
OV10
ICON3
Suboptimal residual disease
GOG111
GOG-132
OV10
ICON3
Differences in research arms platinum agent
Cisplatin used in research arm
GOG111
GOG-132
OV10
Carboplatin used in research arm
ICON3
cyclophosphamide/cisplatin
GOG111
OV10
single agent platinum or CAP
GOG-132
ICON3 carbo
ICON3 (CAP)
Differences in research arms paclitaxel schedule
3 hour infusion of paclitaxel
OV10
ICON3
24 hour infusion of paclitaxel
GOG111
GOG-132
Results grouped by control arm
Paclitaxel/platinum better Platinum-based better Paclitaxel/platinum better Platinum-based better
c2 het = 10.10 (2 d.f.)
P = 0.006
c
2 het = 8.00 (2 d.f.)
P = 0.002
c
2 het = 1.79 (1 d.f.)
P = 0.18
c
2 het = 11.22 (3 d.f.)
P = 0.01
c2 het = 5.05 (1 d.f.)
P = 0.03
c
2 het = 9.27 (1 d.f.)
P = 0.002
c
2 het = 10.79 (2 d.f.)
P = 0.005
c
2 het = 0.64 (1 d.f.)
P = 0.42
c
2 het = 1.33 (2 d.f.)
P = 0.5
0.5                      1                     1.5
c2 het = 6.90 (2 d.f.)
P = 0.03
c2 het = 1.14 (1 d.f.)
P = 0.29
c
2 het = 10.85 (3 d.f.)
P = 0.01
c2 het = 6.40 (1 d.f.)
P = 0.01
c2 het = 7.93 (1 d.f.)
P = 0.005
c
2 het = 8.6 (2 d.f.)
P = 0.01
c
2 het = 0.022 (2 d.f.)
P = 0.99
0.5                      1                     1.5
c2 het = 1.17 (1 d.f.)
P = 0.28
c
2 het = 14.71 (2 d.f.)
P = 0.001
Figure 2 Results grouped by possible factors for heterogeneity.
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It is possible for results of trials to differ because of differences in
the types of patients involved, that is if certain treatments were
more effective in some groups of patients than others. The types
of patients included in each of the four trials are summarised in
Table 3. Figure 2 shows the results of the trials grouped by the
volume of residual disease remaining after surgery, with ‘subopti-
mal’ deﬁned as 41 cm residual disease volume for GOG-111,
GOG-132 and OV10, and 42 cm for ICON3; with the optimal
groups being deﬁned as the converse of these.
Comparing groups with optimally and suboptimally debulked
disease, there is still substantial heterogeneity within groups.
Heterogeneity between groups is not substantially greater than that
within groups for progression-free (F1,4=0.42, P=0.55) or overall
survival (F1,4=1.21, P=0.33).
This suggests that the heterogeneity in the results of these trials
cannot be accounted for by differences in effectiveness for different
types of patient.
THE RESEARCH ARMS
Differences in the effectiveness of the research regimens used in the
trials could account for the heterogeneous results observed. There
are two differences in the paclitaxel/platinum regimens used in
these trials. One is the scheduling of paclitaxel, 3 h infusion (with
a dose of 175 mg m
72) or 24 h infusion (with a dose of
135 mg m
72), and the other is the platinum agent used, cisplatin
or carboplatin.
Three trials (du Bois et al, 1999; Ozols et al, 1999; Neijt et al,
2000) have been conducted comparing cisplatin/paclitaxel against
carboplatin/paclitaxel, one using different paclitaxel schedules on
the two arms (see Table 4). Preliminary results of these trials do
not suggest any difference in survival outcomes between the regi-
mens compared; for this reason paclitaxel/carboplatin using a 3 h
schedule of paclitaxel at 175 mg m
2 is currently preferred on the
basis of the more favourable toxicity proﬁle of carboplatin and
convenience of a shorter schedule (Markman et al, 1998; Neijt et
al, 2000). However, this recommendation is based on preliminary
data and more mature data should be available in the next year
or so.
Looking within each group of results (Figure 2), by paclitaxel
schedule and by platinum agent, there is still substantial heteroge-
neity within the groups. Comparing groups using different
schedules of paclitaxel, heterogeneity between groups is not signif-
icantly greater than within groups; for progression-free survival
(F1,2=0.01, P=0.94) or overall survival (F1,2=0.18, P=0.71) (see
Table 2).
Comparing groups using different platinum agents in combina-
tion with paclitaxel, there is no evidence that heterogeneity
between groups is substantially greater than within groups; for
progression-free survival (F1,2=0.66, P=0.50) or overall survival
(F1,2=1.63, P=0.33).
These results suggest that the heterogeneity in the results of
these trials cannot be accounted for by differences in the research
arms.
THE CONTROL ARMS
The effectiveness of the control regimen, as well as that of the
research regimen, is also of considerable importance in interpreting
the results of any comparative trial.
Four different control regimens were used in these trials. GOG-
111 and OV10 both used cyclophosphamide 750 mg m
72
combined with cisplatin 75 mg m
72; GOG-132 used single agent
cisplatin 100 mg m
72; ICON3 allowed a choice (speciﬁed before
randomisation) of carboplatin, dosed according to the area under
the concentration-time curve (AUC) method (Calvert et al, 1989)
at a minimum AUC of 6, or the combination of cyclophosphamide
500 mg m
72, doxorubicin 50 mg m
72 and cisplatin 50 mg m
72.
The control regimens used in all trials were given 3 weekly for 6
cycles.
The two control regimens used in ICON3 have been shown to
be equivalent in terms of effectiveness in the earlier ICON2 trial
(ICON Collaborators, 1998). A number of trials comparing carbo-
platin and cisplatin have been conducted; the meta-analysis of
these trials performed by the Advanced Ovarian Cancer Trialists
Group (AOCTG) shows no evidence of any difference in effective-
ness between these two platinum analogues (AOCTG, 1998). In
Table 2 Heterogeneity between and within groups
Total within group Between group Heterogeneity
heterogeneity heterogeneity between:within
Characteristic End-point w
2 d.f. P w
2 d.f. P F d.f. P
Degree of crossover prior to progression PFS 10.10 2 0.006 4.27 1 0.038 0.85 1, 2 0.45
little vs substantial OS 14.31 2 0.0008 1.31 1 0.25 0.18 1, 2 0.71
Degree of crossover on progression PFS 8.00 2 0.018 6.37 1 0.012 1.59 1, 2 0.33
little vs substantial OS 6.90 2 0.032 8.72 1 0.003 2.53 1, 2 0.25
Type of patient PFS 13.01 4 0.011 1.36 1 0.24 0.42 1, 4 0.55
optimal vs suboptimal residual disease OS 11.99 4 0.017 3.63 1 0.057 1.21 1, 4 0.33
Paclitaxel schedule PFS 14.32 2 0.0008 0.05 1 0.82 0.007 1, 2 0.94
3 h (175 mg m
72) vs 24 h (135 mg m
72) OS 14.33 2 0.0008 1.29 1 0.26 0.18 1, 2 0.71
Platinum agent used with paclitaxel PFS 10.79 2 0.005 3.58 1 0.058 0.66 1, 2 0.50
cisplatin vs carboplatin OS 8.60 2 0.014 7.02 1 0.008 1.63 1, 2 0.33
Control arm PFS 1.98 3 0.58 12.39 1 0.0004 18.77 1, 3 0.023
single agent platinum or CAP vs CP OS 1.19 3 0.76 14.43 1 0.0002 36.38 1, 3 0.009
Note that the F-test is a one-sided test. In this case the hypothesis is that heterogeneity between groups is greater than that within groups. The alternative (that within group
heterogeneity is the greater) is of no interest here, and has no clear interpretation, but may be tested by inverting the F statistic and reversing the order of the degrees of
freedom.
Table 3 Patients included in each of the four trials
GOG-111 GOG-132 OV10 ICON3
Characteristic (%) (%) (%) (%)
FIGO stage I – – – 9
FIGO stage II – – 7 11
FIGO stage III, optimal – – 30 34
FIGO stage III, IV suboptimal 100 100 63 46
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similar to those used in GOG-132 and ICON3, and the results
indicate that these two regimens are similar in effectiveness
(AOCTG, 1998). The two control arms of ICON3 (single agent
carboplatin and CAP) and that of GOG-132 (single agent cisplatin)
are thus known to be approximately equivalent to each other in
terms of effectiveness. The systematic reviews and meta-analyses
conducted by the AOCTG (AOCTG, 1998) and ourselves (Sander-
cock, 1998) did not reveal any trials comparing any of these three
regimens against the cyclophosphamide/cisplatin regimen used in
GOG-111 and OV10. Figure 2 therefore shows the trials grouped
according to the control regimens with GOG-111 and OV10 form-
ing one group using the control regimen of cyclophosphamide and
cisplatin and the ICON3 and GOG-132 trials forming the other
group.
For both progression-free and overall survival there is no
evidence of heterogeneity between GOG-111 and OV10, (P=0.42
and P=0.28 respectively). There is also no evidence of heterogeneity
between the results of the trials which used a control arm of either
single agent carboplatin, cisplatin or CAP (P=0.51 for progression-
free survival, P=0.99 for overall survival). There is, of course, still
substantial heterogeneity overall, but this is largely between these
two groups. The F-ratio for progression-free survival is 18.77
(1,3 d.f.), P=0.023 and for overall survival is 36.38 (1,3 d.f.),
P=0.009, indicating that for both endpoints there is substantially
more heterogeneity between groups than within groups and that
this difference is unlikely to have arisen by chance.
This analysis indicates that one explanation which is consistent
with the conﬂicting results is that the control regimen used in
GOG-111 and OV10 was not as good as the control regimens
used in ICON3 and GOG-132. The external evidence base for
the control regimens differing in their effectiveness is examined
below.
EXTERNAL EVIDENCE-BASE FOR THE CONTROL-ARM
EXPLANATION
Having found a plausible and consistent explanation for the
heterogeneity in the results of these trials, it is important to inves-
tigate further to check that this explanation is also consistent with
data from other trials. In the following discussion we will focus on
randomised controlled trials (RCTs) identiﬁed through three
systematic reviews: (1) the systematic review and meta-analyses
conducted by the Advanced Ovarian Cancer Trialists Group based
on individual patient data from 37 trials relating to the use of
platinum (AOCTG, 1998); (2) the results of a literature search
performed for a systematic review of platinum dose and dose
intensity in ovarian cancer (Sandercock, 1998). The electronic
search strategy (cut-off date June 1998) was designed to pick up
all references to RCTs in ovarian cancer which involved a platinum
agent, and (3) the Ovarian Cancer Meta-analysis project (Ovarian
Cancer Meta-analysis Project, 1991) based on individual patient
data from four trials of cyclophosphamide/cisplatin (CP) vs cyclo-
phosphamide, doxorubicin and cisplatin (CAP).
The two control regimens used in ICON3, which are denoted
CAP(500,50,50) and carbo(6) using notation in brackets to represent
the doses of individual drugs, have been shown in ICON2 to be
closely equivalent (ICON Collaborators, 1998); the estimated hazard
ratio for progression-free survival is 0.92 with 95% conﬁdence inter-
val (0.81–1.04) and for overall survival is 1.00 (0.86–1.16).
The control regimen in GOG-132, single agent cisplatin at
100 mg m
72, P(100), has not been compared directly with either
of these two regimens, but there is substantial evidence from indi-
vidual patient data meta-analysis that cisplatin and carboplatin are
equivalent, both as single agents and in combination regimens
(AOCTG, 1998). In particular, this meta-analysis included three
trials which had compared single agent cisplatin at 100 mg m
72
against single agent carboplatin at 400 mg m
72 (Adams et al,
1989; Mangioni et al, 1989; Taylor et al, 1994). These trials indi-
vidually and together indicated equivalence between these
regimens; the pooled hazard ratio was 1.01 (95%CI 0.81, 1.26)
with no evidence of heterogeneity (w
2
(het)=0.02, P=0.99). Although
it is not possible to translate carboplatin doses calculated on the
basis of body surface area directly to doses calculated by the AUC
method, the protocol dose in ICON3 equates to an average body
surface area (BSA) dose of around 350–400 mg m
72. There is
thus a substantial body of randomised evidence demonstrating
that all three of the control regimens used in GOG-132 and
ICON3 are similar in effectiveness.
The systematic reviews did not identify any randomised evidence
comparing the cyclophosphamide (750 mg m
72) and cisplatin
(75 mg m
72), CP(750,75), regimen used in GOG-111 and OV10
to any of the regimens used in either GOG-132 or ICON3 and
therefore it is not possible to investigate its comparative efﬁcacy.
It would certainly be unethical to conduct any further trials using
CP(750,75) as there is clear evidence that it is substantially less
effective than paclitaxel/cisplatin. There is, however, some indirect
evidence about this regimen.
Concern about the choice of CP(750,75) as a control arm in
GOG-111 was ﬁrst raised in 1996 (Parmar and Sandercock,
1996) when the results of this trial were ﬁrst published, prior to
any results being available from the other trials. This concern
was based on the results of the Ovarian Cancer Meta-analysis
Project (1991), which used updated individual patient data from
trials comparing cyclophosphamide and cisplatin (CP) with cyclo-
phosphamide, doxorubicin and cisplatin (CAP). The estimated
hazard ratio for overall survival was 0.85 in favour of CAP (95%
conﬁdence interval around this estimate of 0.75–0.98).
However, three of the four trials included in this meta-analysis
gave CP and CAP at intervals of 4 weeks; CP and CAP were given
at 3 week intervals in GOG-111, OV10 and ICON3. Furthermore,
the trials included in the meta-analysis used CP regimens with
doses of 500–1000 mg m
72 of cyclophosphamide and 50–
60 mg m
72 of cisplatin, whereas GOG-111 and OV10 used cyclo-
phosphamide at 750 mg m
72 and cisplatin at 75 mg m
72. Thus
this meta-analysis cannot conﬁrm the size of any difference
between CAP (500, 50, 50) and CP (750, 75), both given for 6
cycles at 3 week intervals.
Although CP (750, 75) became widely used in the late 1980s and
early 1990s, the justiﬁcation supporting it comes from a trial
reported in 1989 and updated in 1996. The justiﬁcation for this
CP (750, 75) regimen appears to be based, at least in part, on
Table 4 Trials comparing paclitaxel/cisplatin against paclitaxel/carboplatin
Trial Paclitaxel/cisplatin Paclitaxel/carboplatin Accrual Results HR (95%CI)
Dutch/Danish (Neijt et al, 2000) Paclitaxel 175 mg m
72, 3 h Paclitaxel 175 mg m
72, 3 h 208 PFS: 1.07 (0.78, 1.48)
Cisplatin 75 mg m
72 Carboplatin 5 AUC OS: not yet reported
AGO (du Bois et al, 1999) Paclitaxel 185 mg m
72, 3 h Paclitaxel 185 mg m
72, 3 h 798 PFS: 1.08 (90.9, 1.3)
Cisplatin 75 mg m
72 Carboplatin 6 AUC OS: not fully reported (P=0.47)
GOG-158 (Ozols et al, 1999) Paclitaxel 135 mg m
72, 24 h Paclitaxel 175 mg m
72, 3 h 840 PFS: 0.91 (0.76, 1.10)
Cisplatin 75 mg m
72 Carboplatin 7.5 AUC OS: not yet reported
First-line treatment for advanced ovarian cancer
J Sandercock et al
821
ã 2002 Cancer Research UK British Journal of Cancer (2002) 87(8), 815–824the results of a Scottish Group trial comparing CP (750,50) with
CP (750,100), both given for 6 cycles at 3 week intervals. This trial,
with 159 patients, suggested a beneﬁt to CP (750,100), with an esti-
mated hazard ratio for overall survival of 0.68 (95% CI 0.46–0.99),
but with considerably greater toxicity observed in this arm (Kaye et
al, 1996). Although not tested in the trial CP (750,75) became
widely used as a standard treatment in Europe and North America
on the basis of a clinical compromise between possibly greater
effectiveness but greater toxicity of the higher dose regimen (Kaye
et al, 1996, McGuire et al, 1996). In their discussion of the Scottish
trial results, Kaye et al (1996) noted that key questions regarding
the optimal dose of platinum remained unanswered, but that
research questions were becoming increasingly focused on the
taxanes. They expressed the belief that the dose of platinum would
continue to be investigated within this new generation of trials.
The only published trials we have identiﬁed which have directly
used the CP(750,75) regimen, have used it as the control regimen
against experimental treatments: three of the trials discussed in
this study, GOG-111, OV10 and GOG-114, comparing it with
paclitaxel/cisplatin; an Italian trial investigating weekly cisplatin
(Bolis et al, 1997), and a Dutch trial investigating a complex 4
drug regimen given 5 weekly (Neijt et al, 1987). One very small
German trial included a similar CP regimen, comparing CP
(700,70) given 4 weekly, CAP (700, 70, 70) given 4 weekly and
P (100) given 2 weekly; this trial randomised only 60 patients,
20 in each arm, and so the results are relatively uninformative
(Richter et al, 1990).
There is therefore no direct evidence concerning the effective-
ness of cyclophosphamide 750 mg m
72 and cisplatin 75 mg m
72
compared with any of the control regimens used in GOG-132
and ICON3. However, the limited indirect evidence available from
the OCMP meta-analysis (Ovarian Cancer Meta-analysis Project,
1991), along with the results of ICON2 (ICON Collaborators,
1998) and the AOCTG meta-analysis (AOCTG, 1998), does
support the hypothesis that the cyclophosphamide/cisplatin control
regimen used in GOG-111 and OV10 may be less effective than the
control regimens used in GOG-132 and ICON3.
The suggestion that single agent platinum (cisplatin or carbo-
platin) may be more effective than a platinum-based
combination (cyclophosphamide/cisplatin) may appear to be at
odds with some of the data from the AOCTG meta-analysis. This
included a summary of all randomised trials comparing single
agent platinum against platinum in combination.
The pooled results of all of these trials suggested a beneﬁt to
combination regimens (AOCTG, 1998). However, it is useful to
examine that analysis in more detail, separating the trials into those
which used platinum at the same dose in both the single agent and
combination arms and those that increased the dose in the single
agent arm. A summary of these trials split in this way is given in
Table 5 and the meta-anaylsis plots are given in Figure 3.
Table 5 Trials comparing single agent platinum vs platinum in combination
No. of patients
Group Trial Single agent Combination entered
Same platinum dose in both arms MT Sinai (Cohen et al, 1983) P (50)6? AP (50)6?3 6
GICOG (GICOG, 1992) P (50)66 CAP (50)66 562
UK South West (Gilby et al, unpublished) P (60)65 IP (60)652 9
Higher platinum in single agent arm SGCTG (Rankin et al, 1992) J (400)66C
LB (300)66 161
HECOG1 (Skarlos et al, 1996) J (400)66 AJ (300)66 130
Piraeus (Athanassiou et al, 1997) J (400)66 BIJ (350)664 0
Milan (Tomirotti et al, 1998) P (60)6? CAP (50)6?4 4
Trials which cannot be classiﬁed in either group UK South West
a (Gilby et al, unpublished) J (?)65 IJ (?)655
Royal Marsden
b (Wiltshaw et al, 1986) P (100)65+P (20)67C
LBP (20)612 87
Figures in brackets show dose of platinum used in the regimen.
aDose of carboplatin not known.
bPlatinum dose in combination very small and trial therefore excluded (results
were very extreme in favour of single agent; inclusion of this trial would substantially increase the apparent beneﬁt of single agent compared to combination treatment). ?=no. of
cycles not known. P=Cisplatin. J=Carboplatin. A=Doxorubicin. C=Cyclophosphamide. C
LB=Chlorambucil. B=Bleomycin. I=Ifosfamide.
0                     0.5                      1                      1.5                     2  
Combination better Single better
Hazard ratio
HR=1.01 95%CI (0.79, 1.28)
(no. events/no. entered)
Combination Single O-E Variance
Higher dose of platinum as a single agent
SGCTC
HECOG 1
Piraeus
Milan
77/85
39/73
12/20
15/21
69/76
37/57
15/20
14/23
1.69
–1.31
3.07
–2.99
36.16
18.80
6.49
6.93
Same platinum dose single agent and combination arms
MT Sinai
GOCOG
UK South West
15/18
162/179
10/13
17/18
320/383
10/17
1.08
–21.27
–3.27
7.91
98.97
4.29
c
2 het = 2.909  P = 0.406
c
2 het = 2.260  P = 0.32
HR=0.81 95%CI (0.67, 0.98)
Figure 3 Randomised trials comparing platinum as a single agent with platinum in combination (Adapted from AOCTG, 1998).
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dose was used in the single agent arm was 1.01 (95% CI 0.79–
1.28; P=0.96). This result of approximate equivalence is now also
supported by ICON2 (hazard ratio of 1.00, 95% CI 0.86–1.16),
and of course, GOG-132. We are grateful to a referee for pointing
out a third trial published since the AOCTG update which rando-
mised 176 women to receive either single agent cisplatin
75 mg m
72 or the combination of cyclophosphamide
500 mg m
72 and cisplatin 50 mg m
72. This trial (Marth et al,
1998) also supports the results shown in Figure 3, with a reported
hazard ratio of 1.1 (95% CI 0.9, 1.3). It should be noted that the
small Royal Marsden trial (Wiltshaw et al, 1986) would fall most
naturally into this group of trials. Its extreme results in favour of
the single agent would support and therefor enhance the argu-
ment made here, but we have not included it because it may
be argued that a very low dose intensity of platinum was used
in the combination arm.
In contrast when the platinum dose was not increased in the
single agent compared to the combination arms, a hazard ratio
for overall survival of 0.81 is observed (95% CI 0.67–0.98,
P=0.03) in favour of combination treatment.
DISCUSSION
Four hypotheses which have been proposed to explain the hetero-
geneous results of the four trials considered in this study have
been examined. Only one of the proposed explanations appears
to be consistent with the observed data. Differences in the effec-
tiveness of the control regimens used is the only explanation
proposed that can, in principle, account for the conﬂicting results
of these trials.
It is possible that this is a chance ﬁnding and that the true, and
as yet undetermined, explanation is different. It is worth noting,
however, that whilst all of the explanations which have been exam-
ined could apply in theory to any set of trial results, in this case
only one was proposed before any heterogeneity was observed;
evidence suggesting that the control regimen used in GOG-111
was sub-optimal was pointed out before any heterogeneity had
been observed (Parmar and Sandercock, 1996), that is before any
results from OV10, GOG-132 or ICON3 were available.
It might be useful to further investigate these questions through
meta-analysis based on individual patient data, and in particular to
investigate the possible inﬂuence of patient characteristics on the
results of these trials. In the meantime, the analyses and other
evidence presented in this paper indicate the importance of giving
platinum (either cisplatin or carboplatin) at optimal doses for the
ﬁrst-line treatment of women with advanced ovarian cancer. Given
all of the randomised evidence on the effectiveness and toxicity of
single agent cisplatin at 100 mg m
72, of the CAP (500, 50 and
50 mg m
72) combination and of all of the paclitaxel/platinum
combinations, we conclude that optimal dose single agent carbo-
platin is a safe and effective ﬁrst-line treatment for women with
advanced ovarian cancer.
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